Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.45 |
| ▸ | MMP1 | P03956 | 14/20 | 0.44 |
| ▸ | MMP9 | P14780 | 13/20 | 0.44 |
| ▸ | MMP12 | P39900 | 13/20 | 0.44 |
| ▸ | MMP2 | P08253 | 11/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.35 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.35 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8088775 | 0.79 | GPR84 (0.49) | GPR84MMP1MMP9MMP12MMP2 | |
| SCHEMBL31446424 | 0.77 | GPR84 (0.46) | GPR84MMP1MMP9MMP12MMP2 | |
| SCHEMBL14038368 | 0.76 | GPR84 (0.50) | GPR84MMP1MMP9MMP12MMP2 | |
| SCHEMBL13546077 | 0.74 | CYP1A2 (0.40) | CYP1A2 | |
| SCHEMBL17761925 | 0.73 | GPR84 (0.50) | GPR84MMP1MMP9MMP12MMP2 | |
| SCHEMBL21102086 | 0.70 | GPR84 (0.47) | GPR84MMP1MMP9MMP12MMP2 | |
| SCHEMBL9264319 | 0.70 | GPR84 (0.56) | GPR84MMP1MMP9MMP12MMP2 | |
| SCHEMBL1161426 | 0.70 | — | — | |
| SCHEMBL2632725 | 0.70 | — | — | |
| SCHEMBL4596046 | 0.69 | GPR84 (0.54) | GPR84MMP1MMP9MMP12MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080292587-A1 | OXIMYL DIPEPTIDE HEPATITIS C PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2008-11-27 | — | — | US | disclosed |
| US-20080292587-A1 | OXIMYL DIPEPTIDE HEPATITIS C PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2008-11-27 | — | — | US | disclosed |
| WO-2008134398-A1 | OXIMYL DIPEPTIDE HEPATITIS C PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2008-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080292587-A1 | OXIMYL DIPEPTIDE HEPATITIS C PROTEASE INHIBITORS | DPP4, PREP, PEPD | GPR84 1524/4885MMP1 593/4885MMP9 673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.